These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18485268)

  • 1. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.
    Kamal-Bahl SJ; Burke TA; Watson DJ; Wentworth CE
    Curr Med Res Opin; 2008 Jun; 24(6):1817-21. PubMed ID: 18485268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.
    Kamal-Bahl SJ; Burke T; Watson D; Wentworth C
    Am J Cardiol; 2007 Feb; 99(4):530-4. PubMed ID: 17293198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
    Balu S; Simko RJ; Quimbo RM; Cziraky MJ
    Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia.
    Caspard H; Chan AK; Walker AM
    Clin Ther; 2005 Oct; 27(10):1639-46. PubMed ID: 16330301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin.
    LaFleur J; Thompson CJ; Joish VN; Charland SL; Oderda GM; Brixner DI
    Ann Pharmacother; 2006; 40(7-8):1274-9. PubMed ID: 16849622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
    Robertson TA; Cooke CE; Wang J; Shaya FT; Lee HY
    Am J Manag Care; 2008 Nov; 14(11):710-6. PubMed ID: 18999905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.
    Ambegaonkar BM; Wentworth C; Allen C; Sazonov V
    Metabolism; 2011 Jul; 60(7):1038-44. PubMed ID: 21185576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation rates of cholesterol-lowering medications: implications for primary care.
    Hiatt JG; Shamsie SG; Schectman G
    Am J Manag Care; 1999 Apr; 5(4):437-44. PubMed ID: 10387383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.